0000000000136722

AUTHOR

Elena Cortés-vicente

showing 3 related works from this author

Clinical characteristics and outcomes of thymoma-associated myasthenia gravis

2021

[Background and purpose] Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.

medicine.medical_specialtyThymomaThymomaEnfermedad del sistema nerviosoMiastenia gravischemical and pharmacologic phenomenaGastroenterology03 medical and health sciences0302 clinical medicineDisease severityRecurrenceInternal medicinehemic and lymphatic diseasesMyasthenia GravismedicineHumansIn patient030212 general & internal medicineneoplasmsNeurologíaMyasthenia gravisRetrospective Studiesbusiness.industryHazard ratioOdds ratioThymus Neoplasmsthymomamedicine.diseaseThymectomyPrognosisConfidence intervalMyasthenia gravisThymomEfectos fisiológicossurgical procedures operativeNeurologyMulticenter studySignos y síntomasNeurology (clinical)Neoplasm Recurrence LocalbusinessTimoma030217 neurology & neurosurgery
researchProduct

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset

2020

[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).

AdultMalePediatricsmedicine.medical_specialtyThymomagenetic structuresCross-sectional studyInvestigación médicaEnfermedad del sistema nerviosoMEDLINEMiastenia gravisLate onsetDISEASECLASSIFICATIONArticleACETYLCHOLINE-RECEPTOR03 medical and health sciences0302 clinical medicineimmune system diseasesMyasthenia GravismedicineEnfermedades neuromuscularesHumansRITUXIMAB030212 general & internal medicineAge of OnsetAgedbusiness.industryAnálisis de datosMiddle Agedmedicine.diseaseMyasthenia gravisnervous system diseasesCross-Sectional StudiesTreatment OutcomeMulticenter studyANTIBODIESAUTOANTIBODIESFemaleObservational studyNeurology (clinical)Age of onsetbusiness030217 neurology & neurosurgeryMUSK
researchProduct

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

2018

ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…

0301 basic medicinemedicine.medical_specialtyTime to relapseRelapse rateGastroenterologyAssaigs clínics de medicaments03 medical and health sciencesMalalties del sistema nerviós0302 clinical medicineimmune system diseasesInternal medicineMedicineIn patientRelapse riskAdverse effectSurvival analysisbusiness.industryGeneral NeuroscienceNervous system DiseasesDrug testingmedicine.diseaseMyasthenia gravis030104 developmental biologyRituximabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct